A Parallel Phenotypic Versus Target-Based Screening Strategy for RNA-Dependent RNA Polymerase Inhibitors of the Influenza A Virus.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
05 09 2019
Historique:
received: 11 07 2019
revised: 03 09 2019
accepted: 04 09 2019
entrez: 8 9 2019
pubmed: 8 9 2019
medline: 4 9 2020
Statut: epublish

Résumé

Influenza A virus infections cause significant morbidity and mortality, and novel antivirals are urgently needed. Influenza RNA-dependent RNA polymerase (RdRp) activity has been acknowledged as a promising target for novel antivirals. In this study, a phenotypic versus target-based screening strategy was established to identify the influenza A virus inhibitors targeting the virus RNA transcription/replication steps by sequentially using an RdRp-targeted screen and a replication-competent reporter virus-based approach using the same compounds. To demonstrate the utility of this approach, a pilot screen of a library of 891 compounds derived from natural products was carried out. Quality control analysis indicates that the primary screen was robust for identification of influenza A virus inhibitors targeting RdRp activity. Finally, two hit candidates were identified, and one was validated as a putative RdRp inhibitor. This strategy can greatly reduce the number of false positives and improve the accuracy and efficacy of primary screening, thereby providing a powerful tool for antiviral discovery.

Identifiants

pubmed: 31491939
pii: v11090826
doi: 10.3390/v11090826
pmc: PMC6783926
pii:
doi:

Substances chimiques

Antiviral Agents 0
RNA, Viral 0
Viral Proteins 0
RNA-Dependent RNA Polymerase EC 2.7.7.48

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Viruses. 2018 Nov 30;10(12):
pubmed: 30513600
Antiviral Res. 2018 May;153:85-94
pubmed: 29524445
Virol J. 2015 Nov 24;12:194
pubmed: 26596270
Viruses. 2018 Jun 13;10(6):
pubmed: 29899269
Viruses. 2018 Nov 30;10(12):
pubmed: 30513620
Adv Pharmacol. 2013;67:217-46
pubmed: 23886002
Jpn J Infect Dis. 2007 Jul;60(4):202-4
pubmed: 17642534
Front Microbiol. 2016 Mar 31;7:450
pubmed: 27065996
J Virol. 2013 Aug;87(15):8272-81
pubmed: 23698304
J Virol. 2016 Jul 27;90(16):7368-7387
pubmed: 27252534
Acta Pharm Sin B. 2014 Aug;4(4):301-6
pubmed: 26579399
Antiviral Res. 2016 Jan;125:34-42
pubmed: 26593979
Methods. 2011 Oct;55(2):188-91
pubmed: 21867756
J Antimicrob Chemother. 2016 Sep;71(9):2489-97
pubmed: 27272726
F1000Res. 2017 Jun 5;6:783
pubmed: 28649374
IUBMB Life. 2018 Jan;70(1):9-22
pubmed: 29210173
Influenza Other Respir Viruses. 2017 May;11(3):240-246
pubmed: 28146320
Nature. 2009 Apr 16;458(7240):914-8
pubmed: 19194459
Comput Biol Chem. 2019 Feb;78:273-281
pubmed: 30597438
Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7
pubmed: 21973296
Sci Rep. 2016 Mar 09;6:22880
pubmed: 26956222
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6247-52
pubmed: 22474359
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28193653
Nature. 2008 Aug 28;454(7208):1123-6
pubmed: 18615018
J Med Chem. 2016 Sep 8;59(17):7699-718
pubmed: 27046062
Antiviral Res. 2018 Sep;157:38-46
pubmed: 29981793
Nature. 2009 Apr 16;458(7240):909-13
pubmed: 19194458
Antiviral Res. 2013 Nov;100(2):446-54
pubmed: 24084488
PLoS One. 2015 Jul 21;10(7):e0133558
pubmed: 26196128
Sci Rep. 2013;3:1106
pubmed: 23346363
J Virol. 1999 Jan;73(1):631-7
pubmed: 9847368
Antiviral Res. 2018 Dec;160:109-117
pubmed: 30316915
Emerg Infect Dis. 2017 Aug;23(8):1355-1359
pubmed: 28580900
Sci Rep. 2017 Aug 24;7(1):9385
pubmed: 28839261
J Med Chem. 2014 Aug 14;57(15):6668-78
pubmed: 25019388
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19151-6
pubmed: 20974907
J Med Chem. 2015 May 14;58(9):3830-42
pubmed: 25856229
Front Med (Lausanne). 2019 May 28;6:109
pubmed: 31192211
J Biol Chem. 2016 Jan 1;291(1):363-70
pubmed: 26559973
Curr Med Chem. 2018;25(38):5115-5127
pubmed: 28933281
J Biol Chem. 2003 May 30;278(22):20381-8
pubmed: 12646557
Clin Infect Dis. 2017 Aug 1;65(3):383-388
pubmed: 28407105

Auteurs

Xiujuan Zhao (X)

College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China. xiujuan95@163.com.

Yanyan Wang (Y)

College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.

Qinghua Cui (Q)

College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China. cuiqinghua1122@163.com.
Shandong Provincial Collaborative Innovation Center for Antiviral Traditional Chinese Medicine, Jinan 250355, China. cuiqinghua1122@163.com.
Qingdao Academy of Chinese Medicinal Sciences, Shandong University of Traditional Chinese Medicine, Qingdao 266122, China. cuiqinghua1122@163.com.

Ping Li (P)

College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China. liping9309@163.com.

Lin Wang (L)

College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China. lynn942@163.com.

Zinuo Chen (Z)

College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China. chenzinuo96@163.com.

Lijun Rong (L)

Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA. lijun@uic.edu.

Ruikun Du (R)

College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China. duzi857@163.com.
Shandong Provincial Collaborative Innovation Center for Antiviral Traditional Chinese Medicine, Jinan 250355, China. duzi857@163.com.
Qingdao Academy of Chinese Medicinal Sciences, Shandong University of Traditional Chinese Medicine, Qingdao 266122, China. duzi857@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH